Highest-materiality recent filing
Phathom Pharma Q1 net rev $58.3M (+104% YoY); maintains FY 2026 op profitability guidance
Q1 net revenues $58.3M vs $28.5M YoY; net loss $30.4M vs $94.3M YoY.
Q4 net revenues $57.6M; FY2025 net revenues $175.1M, a 217% increase over FY2024.
Phathom Pharmaceuticals prices $130M public offering of common stock and pre-funded warrants
6,875,000 shares of common stock at $16.00/share and pre-funded warrants for 1,250,078 shares at $15.999/warrant.
Q4 2025 net revenues expected ~$57-58M; full year 2025 net revenues ~$174.5-175.5M.
Phathom Q3 revenue $49.5M, up 25% QoQ; net loss $30M; FY guidance raised to $170-175M
Net revenue of $49.5M in Q3 2025, up 25% from Q2 and from $16.4M in Q3 2024.
Phathom publishes Phase 3 NERD data showing VOQUEZNA improves nocturnal GERD symptoms
At week 4, VOQUEZNA 10 mg and 20 mg achieved 59.9% and 56.4% heartburn-free nights vs 43.3% placebo (nominal p<0.0001).
Phathom Q2 revenue $39.5M, up from $7.3M YoY; 580k+ VOQUEZNA scripts filled
Net revenues $39.5M in Q2 2025 vs $7.3M in Q2 2024; net loss $75.8M vs $91.4M YoY.
FDA Orange Book corrected; VOQUEZNA NCE exclusivity confirmed through May 2032
FDA updated Orange Book to show full 10-year NCE exclusivity for VOQUEZNA (vonoprazan) 10 mg and 20 mg tablets.
FDA grants Phathom citizen petition; VOQUEZNA exclusivity extended to May 2032
FDA approved Phathom's 2024 citizen petition to correct Orange Book for VOQUEZNA (vonoprazan) tablets.
Phathom Q1 net revenue $28.5M, net loss $94.3M; cuts costs, exec changes, targets 2026 profit
Net revenue $28.5M (up from $1.9M YoY); net loss $94.3M ($77.1M non-GAAP adjusted).
CEO transition at Phathom: Steven Basta appointed, Terrie Curran resigns effective March 31, 2025
Steven Basta appointed CEO, President and Class I director effective April 1, 2025; Terrie Curran resigned for personal reasons.
Phathom Pharma Q4 revenue $29.7M; VOQUEZNA prescriptions up 81% QoQ
FY2024 net revenue $55.3M from VOQUEZNA launch; Q4 revenue $29.7M (81% increase vs Q3).
Phathom files Citizen Petition to correct VOQUEZNA Orange Book exclusivity to May 2032
Petition requests FDA correct VOQUEZNA tablet listings to reflect 10-year NCE exclusivity ending May 3, 2032.
Net revenues $16.4M for Q3 2024 (vs $7.3M Q2 2024); no revenues in Q3 2023.
Phathom Pharmaceuticals prices $130M stock/warrant offering; net proceeds ~$121.7M
8,695,652 shares at $11.50/share and pre-funded warrants for 2,608,922 shares at $11.499/warrant.
Phathom Q2 revenue $7.3M, prescriptions up 184%; VOQUEZNA gets FDA approval for Non-Erosive GERD
Net revenues $7.3M in Q2 2024 vs $1.9M in Q1 2024; no Q2 2023 revenue due to launch in late 2023.
Phathom gets FDA approval for VOQUEZNA to treat heartburn in Non-Erosive GERD
FDA approved VOQUEZNA (vonoprazan) 10 mg tablets for relief of heartburn associated with Non-Erosive GERD in adults.
Phathom posts Q1 net loss $82.9M, revenue $1.9M; VOQUEZNA prescriptions top 17,500
Net loss GAAP $82.9M (non-GAAP adj. net loss $64.8M) vs $37.8M loss Q1 2023; revenue $1.9M from VOQUEZNA launch.
The board of directors (the “Board”) of Phathom Pharmaceuticals, Inc. (the “Company”) appointed Theodore R. Schroeder to the Board as a Class I director, effective April 16, 2025
Terrie Curran who resigned as President and Chief Executive Officer and as a member of the Company’s Board of Directors (the “Board”) for personal reasons, effective March 31, 2025.
Steven Basta was appointed as the Chief Executive Officer, President and as a Class I director of Phathom Pharmaceuticals, Inc. (the “Company”), replacing Terrie Curran who resigned as President and Chief Executive Officer and as a member of the Company’s Board of Directors (the “Board”) for personal reasons, effective March 31, 2025.
Max materiality 0.80 · Median 0.75 · Most common event earnings